Abstract
The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2022 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.
Journal Section:
Editor's choice
References
1.
Empfehlungen Gynäkologische Onkologie Kommission Mamma. 2022. Available from: www.ago-online.
2.
André
F
, Ciruelos
E
, Rubovszky
G
, Campone
M
, Loibl
S
, Rugo
HS
, . Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer
. N Engl J Med
. 2019 May
;380
:1929
–40
.3.
Fribbens
C
, O’Leary
B
, Kilburn
L
, Hrebien
S
, Garcia-Murillas
I
, Beaney
M
, . Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer
. J Clin Oncol
. 2016 Sep
;34
:2961
–8
.4.
Hymann
DM
, Piha-Paul
SA
, Won
H
, Rodon
J
, Saura
C
, Shapiro
GI
, . HER kinase inhibition in patients with HER2- and HER3-mutant cancers
. Nature
. 2018 Feb
;554
:189
–94
.5.
Cocco
E
, Scaltriti
M
, Drilon
A
. NTRK fusion-positive cancers and TRK inhibitor therapy
. Nat Rev Clin Oncol
. 2018 Dec
;15
:731
–47
.6.
Bidard
FC
, Peeters
DJ
, Fehm
T
, Nolè
F
, Gisbert-Criado
R
, Mavroudis
D
, . Clinical validity of circulating tumor cells in patients with metastatic breast cancer. A pooled analysis of individual patient data
. Lancet Oncol
. 2014 Apr
;15
(4
):406
–14
.7.
Mosele
F
, Remon
J
, Mateo
J
, Westphalen
CB
, Barlesi
F
, Lolkema
MP
, . Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group
. Ann Oncol
. 2020 Nov
;31
(3
):1491
–505
.8.
Im
SA
, Lu
YS
, Bardia
A
, Harbeck
N
, Colleoni
M
, Franke
F
, . Overall survival with Ribociclib plus endocrine therapy in breast cancer
. N Engl J Med
. 2019 Jul
;381
(4
):307
–16
.9.
Hortobagyi
GN
, Stemmer
SM
, Burris
HA
, Yap
YS
, Sonke
GS
, Hart
L
, . Overall survival with Ribociclib plus letrozole in advanced breast cancer
. N Engl J Med
. 2022 Mar
;386
(10
):942
–50
.10.
Tolaney
SM
, Wardley
AM
, Zambelli
S
, Hilton
JF
, Troso-Sandoval
TA
, Ricci
F
, . Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
. Lancet Oncol
. 2020 Jun
;21
(6
):763
–75
.11.
Schmid
P
, Rugo
HS
, Adams
S
, Schneeweiss
A
, Barrios
CH
, Iwata
H
, . Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
. Lancet Oncol
. 2020 Dec
;21
:44
–59
.12.
Miles
D
, Gligorov
J
, Andre
F
, Cameron
D
, Schneeweiss
A
, Barrios
CH
, . Primary results from impassion131, a double-blind placebo-controlled randmised phase III trial of first-line paclitaxel +/− atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
. Ann Oncol
. 2020 Aug
;31
(Suppl 4
):S1142
–215
.13.
Taylor
AM
, Chan
DLH
, Tio
M
, Patil
SM
, Traina
TA
, Robson
ME
, . PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer
. Cochrane Database Syst Rev
. 2021 Apr
;4
(4
):CD011395
.14.
Tung
NM
, Robson
ME
, Ventz
S
, Santa-Maria
CA
, Nanda
R
, Marcom
PK
, . TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes
. J Clin Oncol
. 2020 Dec
;38
:4274
–82
.15.
Cortés
J
, Kim
SB
, Chung
WP
, Im
SA
, Park
YH
, Hegg
R
, . Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer
. N Engl J Med
. 2022 Mar
;386
(12
):1143
–54
.16.
Murthy
RK
, Loi
S
, Okines
A
, Paplomata
E
, Hamilton
E
, Hurvitz
SA
, . Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
. N Engl J Med
. 2020 Feb
;382
(7
):597
–609
.17.
Tesfamariam
Y
, Jakob
T
, Wöckel
A
, Adams
A
, Weigl
A
, Monsef
I
, . Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: a systematic review and network meta-analysis
. Crit Rev Oncol Hematol
. 2019 May
;137
:1
–8
.18.
Clemons
M
, Ong
M
, Stober
C
, Ernst
S
, Booth
C
, Canil
C
, . A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
. Eur J Cancer
. 2021 Jan
;142
:132
–40
.20.
Srivastava
A
, Nogueras Gonzales
GM
, Geng
Y
, Won
AM
, Cabanillas
ME
, Naing
A
, . Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis
. Support Care Cancer
. 2021 May
;29
(5
):2305
–17
.21.
Kumar
A
, Weber
MH
, Gokaslan
Z
, Wolinsky
JP
, Schmidt
M
, Rhines
L
, . Metastatic spinal cord compression and steroid treatment a systematic review
. Clin Spine Surg
. 2017
;30
(4
):156
–63
.22.
Kuksis
M
, Gao
Y
, Tran
W
, Hoey
C
, Kiss
A
, Komorowski
AS
, . The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis
. Neuro Oncol
. 2021 May
;23
(6
):894
–904
.23.
Le Rhun
E
, Guckenberger
M
, Smits
M
, Dummer
R
, Bachelot
T
, Sahm
F
, . EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
. Ann Oncol
. 2021 Mar
;32
(11
):1332
–47
.24.
Lin
N
, Borges
V
, Anders
C
, Murthy
R
, Paplomata
E
, Hamilton
E
, . Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial
. J Clin Oncol
. 2020 Aug
;38
(23
):610
–2619
.25.
Fitzal
F
, Bjelic-Radisic
V
, Knauer
M
, Steger
G
, Hubalek
M
, Balic
M
, . Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial
. Ann Surg
. 2019 Jun
;269
(6
):1163
–9
.26.
Khan
SA
, Zhao
F
, Solin
LJ
, Goldstein
LJ
, Cella
D
, Basik
M
, . A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: a trial of the ECOG-ACRIN research group (E2108)
. J Clin Oncol
. 2020
;38
(18 Suppl
.27.
Badwe
R
, Hawaldar
R
, Nair
N
, Kaushik
R
, Parmar
V
, Siddique
S
, . Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial
. Lancet
. 2015 Oct
;16
(13
):1380
–8
.28.
Soran
A
, Ozmen
V
, Ozbas
S
, Karanlik
H
, Muslumanoglu
M
, Igci
A
, . Primary surgery with systemic therapy in patients with de Novo stage IV breast cancer: 10-year follow-up; protocol MF07-01 randomized clinical trial
. J Am Coll Surg
. 2021 Dec
;233
(6
):742
–51
.29.
Bjelic-Radisic
V
, Fitzal
F
, Knauer
M
, Steger
G
, Egle
D
, Greil
R
, . Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive trial
. BMC Cancer
. 2020 May
;20
(1
):392
.30.
Soran
A
, Dogan
L
, Isik
A
, Ozbas
S
, Trabulus
DC
, Demirci
U
, . The effect of primary surgery in patients with De Novo stage IV breast cancer with bone metastasis only (Protocol BOMET MF 14-01): a multi-center, prospective registry study
. Ann Surg Oncol
. 2021 Sep
;28
(9
):5048
–57
.31.
Magnoni
F
, Colleoni
M
, Mattar
D
, Corso
G
, Bagnardi
V
, Frassoni
S
, . Contralateral axillary lymph node metastases from breast carcinoma: is it time to review TNM cancer staging
. Ann Surg Oncol
. 2020 Oct
;27
(11
):4488
–99
.32.
Nash
AL
, Thomas
SM
, Plichta
JK
, Fayanju
OM
, Hwang
ES
, Greenup
RA
, . Contralateral axillary nodal metastases: stage IV disease or a manifestation of progressive locally advanced breast cancer
. Ann Surg Oncol
. 2021 Oct
;28
(10
):5544
–52
.33.
Sharma
BB
, Rai
K
, Blunt
H
, Zhao
W
, Tosteson
TD
, Brooks
GA
. Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis
. Oncologist
. 2021 Dec
;26
(12
):1008
–16
.34.
Modi
S
, Saura
C
, Yamashita
T
, Park
YH
, Kim
SB
, Tamura
K
, . Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
. N Engl J Med
. 2020 Feb
;382
(7
):610
–21
.35.
Bardia
A
, Hurvitz
SA
, Tolaney
SM
, Loirat
D
, Punie
K
, Oliveira
M
, . Sacituzumab govitecan in metastatic triple-negative breast cancer
. N Engl J Med
. 2021
;384
(16
):1529
–41
.36.
Barcenas
CH
, Hurvitz
SA
, Di Palma
JA
, Bose
R
, Chien
AJ
, Iannotti
N
, . Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
. Ann Oncol
. 2020 Sep
;31
:1223
–30
.37.
Raschi
E
, Fusaroli
M
, Ardizzoni
A
, Poluzzi
E
, De Ponti
F
. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
. Breast Cancer Res Treat
. 2021 Feb
;186
(1
):219
–27
.38.
Hwang
JP
, Feld
JJ
, Hammond
SP
, Wang
SH
, Alston-Johnson
DE
, Cryer
DR
, . Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update
. J Clin Oncol
. 2020 Nov
;38
:3698
–715
.39.
Cardoso
F
, Paluch-Shimon
S
, Senkus
E
, Curigliano
G
, Aapro
MS
, André
F
, . 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
. Ann Oncol
. 2020 Dec
;31
(12
):1623
–49
.40.
Lin
NU
, Thomssen
C
, Cardoso
F
, Cameron
D
, Cufer
T
, Fallowfield
L
, . International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC task force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer
. Breast
. 2013 Jun
;22
(3
):203
–10
.41.
Ferrell
BR
, Temel
JS
, Temin
S
, Smith
TJ
. Integration of palliative care into standard oncology care: ASCO clinical practice guideline update summary
. J Oncol Pract
. 2017 Jan
;13
(2
):119
–21
.© 2022 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2022
You do not currently have access to this content.
